Drug intelligence / Profile preview

transforming growth factor beta 1

Development stage: Preclinical
Lead developer: Cellumed
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Implant

Overview

**Transforming growth factor beta 1** is a recombinant form of the human multifunctional cytokine TGF-β1 being developed by Cellumed, an InscoBi subsidiary, as a locally implanted tissue-engineering graft material for **knee cartilage regeneration**. Local TGF-β1 delivery is intended to activate TGF-β receptor signaling in cartilage-repair cells, promoting chondrogenesis and extracellular-matrix production to support repair of damaged articular cartilage. The Cellumed program is reported as preclinical.

Other names: TGF-beta1TGF-beta-1TGF-beta 1TGF-β1TGFB1TGFB-1TGFB 1transforming growth factor-β1

Targets

TGFBR1TGFBR2 (TGF-β receptor type 2)TGFBR3 (TGF-β receptor type III)

Beyond the preview

Go deeper on transforming growth factor beta 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on transforming growth factor beta 1.

Explore the full profile